Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

NCT03044730 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Capecitabine
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]